Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » Marijuana Stocks Hot Pick Now: CBIS, CNAB, GBLX

 - UBBFriend: Email this page to someone!    
Author Topic: Marijuana Stocks Hot Pick Now: CBIS, CNAB, GBLX
Doctoall
Member


Icon 1 posted      Profile for Doctoall     Send New Private Message       Edit/Delete Post   Reply With Quote 
MJ stocks are jumping this past week

--------------------
Be Careful Of The Toes We Step On Today, They Could Be Attached To The Butt We Have To Kiss Tomorrow

Posts: 4725 | From: Elk Grove ( Sacramento )CA USA | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
mj stocks look pretty good . what are your picks
Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Doctoall
Member


Icon 1 posted      Profile for Doctoall     Send New Private Message       Edit/Delete Post   Reply With Quote 
Nothing for the week before last week I made mucho bank but after Trump said he was going to crack down on MJ the stocks tanked. So holding some for now and waiting for the dust to settle

--------------------
Be Careful Of The Toes We Step On Today, They Could Be Attached To The Butt We Have To Kiss Tomorrow

Posts: 4725 | From: Elk Grove ( Sacramento )CA USA | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
I like

InMed (CSE: IN) (OTC: IMLFF)

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Contact: InMed Pharmaceuticals Inc.

Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207
E: chris@inmedpharma.com

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
VANCOUVER, BC / ACCESSWIRE / March 2, 2017 / InMed Pharmaceuticals, Inc. ("InMed") (CNSX: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of an international Patent Cooperation Treaty (PCT) application, an important component in providing intellectual and commercial protection for INM-750 as a cannabinoid-based topical therapy for Epidermolysis Bullosa Simplex (EBS).

Epidermolysis Bullosa (EB) is a group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears from friction or trauma. Internal organs and bodily systems can also be affected by EB. It results from a defect of anchoring between the dermis and epidermis caused most frequently by the dysfunction or absence of certain proteins, called keratins, in the skin. EB is an orphan disease with no known treatment and has a significant unmet medical need. INM-750 will be the first therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms.

It is well documented that cannabinoid compounds have unique anti-inflammatory, analgesic and wound healing promoting properties via several mechanisms, thus making them theoretically excellent candidates for use in alleviating some of the symptoms associated with EB. InMed's proprietary Bioinformatics Database Assessment Tool predicted a dual approach that may prove beneficial to patients: first, the ability of certain cannabinoids to play a role in addressing key disease hallmarks (wound healing, infection, pain, itch, inflammation) in all patients with EB; and second, the ability of some cannabinoids to regulate the expression of various keratins that might compensate for the dysfunctional keratins that cause Epidermolysis Bullosa Simplex (EBS). EBS accounts for the vast majority of EB patients. InMed conducted several in vitro and in vivo assays and the results of these studies form the basis of this PCT application.

The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151 member countries within the PCT worldwide, so near global patent coverage can be obtained through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, and many other countries. The original priority date for this filing was May 26, 2015, therefore coverage of any underlying patent claims would extend for 20 years until 2035 in the United States, and may be subject to patent term extensions that would enable years of additional protection.

"This is a significant milestone achieved by our scientific team's discovery and validation of a new cannabinoid therapy to treat a serious disease with high unmet medical need. We are looking forward to fully understanding the potential impact of INM-750 in helping the EB community," said Dr. Sazzad Hossain, Chief Scientific Officer of InMed Pharmaceuticals. "The pre-clinical data emerging on the use of cannabinoids for EB, as well as other disease targets in our drug development portfolio, continue to validate our discovery approach using our bioinformatics assessment tool. These drug/disease targeting predictions are then followed by relatively quick, inexpensive, yet highly informative confirmatory laboratory studies to validate the predictions of the database. This approach is proving to be an important means to shorten drug development timelines as well as significantly reduce development costs."

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Contact: InMed Pharmaceuticals Inc.

Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
Scientific Advisory Board


Dr. Paul Anderson, Ph.D.

Scientific Advisor

Dr. Anderson is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical research and development. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United States. While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into pre-clinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical development. He received his Ph.D. in organic chemistry at the University of Alberta.

Mr. Anderson is also a Consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN).


About Us

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
from wealth daily




March 7th, 2017

Snoop Dogg is not shy about his love of marijuana.

And while his claim to fame is music, not plants, it's actually marijuana that's likely to net him more money than he ever made in the music business.

This is a pretty big deal when you consider his net worth — most of which is the result of his music career — comes in around $135 million.

But today, Snoop is not just a musician — he's an exceptionally gifted entrepreneur. And a sizable portion of his investment dollars is being funneled into incredibly profitable legal marijuana ventures. He even ponied up $25 million to launch his own fund focused on the legal marijuana market.

Of course, this should come as no surprise. After all, Snoop isn't the only celebrity millionaire betting big on marijuana. Guys like former Facebook president Sean Parker, PayPal co-founder Peter Thiel, and even billionaire George Soros have all staked their claim to the legal marijuana market. And with good reason.

You see, the truth is, marijuana is considered to be the largest cash crop in the United States.

Enjoying a growth rate of 77% over the last few years and an estimated 700% growth rate by 2018, it's bigger than corn, bigger than cotton, and bigger than wheat.

In fact, according to UN data, it's valued at about $142 billion.

To put that in perspective, the global coffee market — one of the most valuable commodities on the planet — is valued at about $80 billion per year.

The bottom line is that marijuana is no longer the underground drug that can only be bought on street corners from criminals. It's now a viable industry that's making investors an absolute fortune.

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference

March 8, 2017


Vancouver, BC – March 08, 2017 - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California.

"The ROTH Conference is one of the largest in the nation, and it does a wonderful job introducing small and mid-cap companies to institutional investors who are focused on these emerging opportunities, said Chris Bogart, SVP of Investor Relations. InMed Pharmaceuticals is honored to have been asked to present this assembly of Institutional investors who represent significant resources in the healthcare space, and we believe InMed Pharmaceuticals is a very well positioned, high potential opportunity."

About ROTH Capital Conference

ROTH Capital Partners 29th Annual Conference is one of the largest of its kind in the U.S. Following the success of previous years’ events, the ROTH Conference, with close to 500 participating companies and over 4,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including Healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a ‘must attend’ event for anyone working in the small and mid-cap space. ROTH combines company presentations, Q&A sessions and management one-on-one meetings so that institutional investors can have an in-depth look at company senior management and issues affecting the growth of the presenting companies.

ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in Boston, Chicago, Larkspur, Los Angeles, New York and San Diego as well as Hong Kong.

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Contact: InMed Pharmaceuticals Inc.

Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207
E: chris@inmedpharma.com

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about the company’s positioning as a high potential opportunity in the Healthcare sector and the expected fundamental value drivers of the company. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
raybond
Member


Rate Member
Icon 1 posted      Profile for raybond     Send New Private Message       Edit/Delete Post   Reply With Quote 
Here’s a pot stock on an accelerating upward trajectory: 22nd Century Group (NYSE: XXII), a small-cap biotech that genetically re-engineers marijuana as well as tobacco plants for end uses that are perceived as socially valuable.

22nd Century specializes in tobacco harm reduction and cannabis research. With a market valuation of $125 million, 22nd Century Group is a relatively stable play on a volatile industry that’s rife with shaky, thinly capitalized start-ups.

A different kind of biotech…


22nd Century’s THC-free marijuana is in demand among farmers, medical scientists, and agricultural programs. The company’s researchers are now creating “enabling tools” that expedite the bio-engineering of cannabinoid production in the cannabis plant, with the aim of designing new strains of industrial hemp plants with reduced levels of cannabinoids for new drug treatments and agricultural applications.

Among the company’s key initiatives is the development of a new strain of hemp containing zero THC, the main psychoactive compound found in cannabis. THC produces the “high” in the brain that earns marijuana its federal ban.

On May 1, 22nd Century announced that the U.S. Food and Drug Administration had granted the company authorization to conduct a clinical trial studying the company’s “Brand B” low tar-to-nicotine ratio cigarettes.

The marijuana industry is mostly comprised of smaller players that are burdened with debt and weak (or nonexistent) earnings growth. 22nd Century, however, boasts the balance sheet strength and earnings momentum that should help it weather the sector’s inevitable shakeout.

The company sports a low total debt-to-equity ratio (most recent quarter) of 1.26. The average analyst expectation is that 22nd Century’s year-over-year earnings growth will reach 25% in the current quarter, 25% next quarter, 33.3% this year, and 10% next year.

Posts: 3767 | From: beautiful California | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share